| abstract |
In part, the invention provides a method of treating, preventing, or reducing the severity of, one or more complications of myeloproliferative disorders (e. G., Erythropoietic, pruritic platelet, and myelofibrosis) ≪ / RTI > The invention further relates to a method for treating, preventing, or reducing the severity of one or more of a Janus kinase-associated disorder or a Janus kinase-related disorder. In certain aspects, the invention provides a method of treating or preventing one or more complications of a myeloproliferative disorder (e. G., Intrinsic erythropoiesis, essential thrombocytosis, and myelofibrosis) or a Janus kinase-associated disorder or a myeloproliferative disorder or a Janus kinase- Lt; / RTI > antagonist for the treatment, prevention, or reduction of the severity of the disease. |